Henoch-Schönlein purpura and meningococcal B vaccination.
The risk of Henoch-Schönlein purpura (HSP) following vaccination with a group B meningococcal vaccine was assessed through active hospital safety monitoring. There was no increase in the relative incidence of HSP within 30 days after vaccination nor recurrence in HSP cases who received one or more further vaccine doses (re-challenge).
Sexton
K
K
Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand.
McNicholas
A
A
Galloway
Y
Y
Radke
S
S
Kieft
C
C
Stehr-Green
P
P
Reid
S
S
Neutze
J
J
Drake
R
R
D002648:Child; D002675:Child, Preschool; D003875:Drug Eruptions / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000139:chemically induced* / Q000453:epidemiology; D017589:Immunization Programs; D007115:Immunization Schedule; D015994:Incidence; D007223:Infant; D008297:Male; D022401:Meningococcal Vaccines / Q000009:adverse effects*; D009520:New Zealand / Q000453:epidemiology; D014611:Vaccination / Q000009:adverse effects
D022401:Meningococcal Vaccines